Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRT-064040 nasal spray for acute treatment of migraine
NCT07304518Phase 2Recruiting
- Sponsor
- Sichuan Prite Pharmaceutical
- Start
- Jan 2026
- Primary completion
- Sep 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of PRT-064040 in migraine, sponsored by Sichuan Prite Pharmaceutical. Primary endpoints: Percentage of Participants With Freedom From Pain at 2 Hours Post-dose and Percentage of Participants With Freedom From Most Bothersome Symptom (MBS) at 2 Hours Post-dose. Started Jan 2026; status: recruiting.
02
Drugs
PRT-064040
03
Conditions
migraine
Beyond the preview
Go deeper on NCT07304518.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07304518.